Assessing Current Clinical Developments in Ophthalmic AAV Vector Gene Therapies Delivered by Subretinal and Suprachoroidal Injection
Time: 10:45 am
day: Day Two
Details:
- Exploring the technological background of therapies in development
- Evaluating the progress of ongoing clinical trials
- Addressing existing unmet clinical needs in target disease areas
